MoneyWorks4Me

Clarification sought from Glenmark Pharmaceuticals

30 Oct 2015 Evaluate

The Exchange has sought clarification from Glenmark Pharmaceuticals with reference to news reported on CNBC TV18 on October 29, 2015 -‘Setback For Glenmark: Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule.’

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1757.40
Dr. Reddys Labs. 1179.05
Cipla 1300.25
Lupin 1950.75
Zydus Lifesciences 1110.10
View more..